ReviewFrontiers in oncology2020

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

Elisena Franzese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.